File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1177/17562848231170943
- Scopus: eid_2-s2.0-85158168857
- WOS: WOS:000982600400001
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Long-term effect of Helicobacter pylori eradication on colorectal cancer incidences
Title | Long-term effect of Helicobacter pylori eradication on colorectal cancer incidences |
---|---|
Authors | |
Keywords | clarithromycin-containing triple therapy colorectal cancer epidemiology Helicobacter pylori standardized incidence ratio |
Issue Date | 6-May-2023 |
Publisher | SAGE Publications |
Citation | Therapeutic Advances in Gastroenterology, 2023, v. 16 How to Cite? |
Abstract | Background:There is evidence supporting the association between Helicobacter pylori infection and colorectal cancer (CRC), but whether H. pylori eradication reduces the risk of CRC is still unknown. Objectives:To compare the incidence of CRC in subjects who had received H. pylori eradication therapy with general population. Design:A population-based retrospective cohort study. Methods:This study included all H. pylori-infected subjects who had received their first course of clarithromycin-containing triple therapy in 2003–2015 in Hong Kong. We compared the observed incidences of CRC in this H. pylori eradicated cohort with the expected incidences in the age- and sex-matched general population. The standardized incidence ratio (SIR) with 95% confidence interval (CI) was computed. Results:Among 96,572 H. pylori-eradicated subjects with a median follow-up of 9.7 years, 1417 (1.5%) developed CRC. Primary analysis showed no significant difference in the observed and expected incidences of CRC (SIR: 1.03, 95% CI: 0.97–1.09). However, when stratified according to the follow-up period, higher incidence of CRC was only observed in the first 5 years after eradication (SIR: 1.47, 95% CI: 1.39–1.55), but it was lower (SIR: 0.85, 95% CI: 0.74–0.99) than general population after 11 years. When stratified by tumor location, the observed incidence was higher for colon (SIR: 1.20, 95% CI: 1.12–1.29) but lower for rectal cancer (SIR: 0.90, 95% CI: 0.81–0.999) among H. pylori-eradicated subjects. Conclusions:H. pylori-infected subjects appeared to have a higher incidence of CRC initially, which declined progressively to a level lower than general population 10 years after H. pylori eradication, particularly for rectal cancer. |
Persistent Identifier | http://hdl.handle.net/10722/340849 |
ISSN | 2023 Impact Factor: 3.9 2023 SCImago Journal Rankings: 1.189 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Guo, CG | - |
dc.contributor.author | Zhang, FF | - |
dc.contributor.author | Jiang, F | - |
dc.contributor.author | Wang, LL | - |
dc.contributor.author | Chen, YJ | - |
dc.contributor.author | Zhang, WX | - |
dc.contributor.author | Zhou, AN | - |
dc.contributor.author | Zhang, ST | - |
dc.contributor.author | Leung, WK | - |
dc.date.accessioned | 2024-03-11T10:47:46Z | - |
dc.date.available | 2024-03-11T10:47:46Z | - |
dc.date.issued | 2023-05-06 | - |
dc.identifier.citation | Therapeutic Advances in Gastroenterology, 2023, v. 16 | - |
dc.identifier.issn | 1756-283X | - |
dc.identifier.uri | http://hdl.handle.net/10722/340849 | - |
dc.description.abstract | <h3>Background:</h3><p>There is evidence supporting the association between <em>Helicobacter pylori</em> infection and colorectal cancer (CRC), but whether <em>H. pylori</em> eradication reduces the risk of CRC is still unknown.</p><h3>Objectives:</h3><p>To compare the incidence of CRC in subjects who had received <em>H. pylori</em> eradication therapy with general population.</p><h3>Design:</h3><p>A population-based retrospective cohort study.</p><h3>Methods:</h3><p>This study included all <em>H. pylori</em>-infected subjects who had received their first course of clarithromycin-containing triple therapy in 2003–2015 in Hong Kong. We compared the observed incidences of CRC in this <em>H. pylori</em> eradicated cohort with the expected incidences in the age- and sex-matched general population. The standardized incidence ratio (SIR) with 95% confidence interval (CI) was computed.</p><h3>Results:</h3><p>Among 96,572 <em>H. pylori</em>-eradicated subjects with a median follow-up of 9.7 years, 1417 (1.5%) developed CRC. Primary analysis showed no significant difference in the observed and expected incidences of CRC (SIR: 1.03, 95% CI: 0.97–1.09). However, when stratified according to the follow-up period, higher incidence of CRC was only observed in the first 5 years after eradication (SIR: 1.47, 95% CI: 1.39–1.55), but it was lower (SIR: 0.85, 95% CI: 0.74–0.99) than general population after 11 years. When stratified by tumor location, the observed incidence was higher for colon (SIR: 1.20, 95% CI: 1.12–1.29) but lower for rectal cancer (SIR: 0.90, 95% CI: 0.81–0.999) among <em>H. pylori</em>-eradicated subjects.</p><h3>Conclusions:</h3><p><em>H. pylori</em>-infected subjects appeared to have a higher incidence of CRC initially, which declined progressively to a level lower than general population 10 years after <em>H. pylori</em> eradication, particularly for rectal cancer.</p> | - |
dc.language | eng | - |
dc.publisher | SAGE Publications | - |
dc.relation.ispartof | Therapeutic Advances in Gastroenterology | - |
dc.rights | This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. | - |
dc.subject | clarithromycin-containing triple therapy | - |
dc.subject | colorectal cancer | - |
dc.subject | epidemiology | - |
dc.subject | Helicobacter pylori | - |
dc.subject | standardized incidence ratio | - |
dc.title | Long-term effect of Helicobacter pylori eradication on colorectal cancer incidences | - |
dc.type | Article | - |
dc.identifier.doi | 10.1177/17562848231170943 | - |
dc.identifier.scopus | eid_2-s2.0-85158168857 | - |
dc.identifier.volume | 16 | - |
dc.identifier.eissn | 1756-2848 | - |
dc.identifier.isi | WOS:000982600400001 | - |
dc.identifier.issnl | 1756-283X | - |